SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

WFRF:(Capodanno D)
 

Search: WFRF:(Capodanno D) > (2020) > Angiolillo Dominick J. > Dual-pathway inhibi...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease

Capodanno, Davide (author)
Univ Catania, Azienda Osped Univ Policlin Vittorio Emanuele, CAST PO G Rodolico, Div Cardiol, Catania, Italy
Bhatt, Deepak L. (author)
Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA
Eikelboom, John W. (author)
Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON, Canada; McMaster Univ, Hamilton, ON, Canada
show more...
Fox, Keith A. A. (author)
Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
Geisler, Tobias (author)
Univ Hosp Tubingen, Dept Cardiol & Angiol, Tubingen, Germany
Gibson, C. Michael (author)
Harvard Med Sch, Beth Israel Deaconess Med, Dept Med, Cardiovasc Div, Boston, MA 02115 USA
Gonzalez-Juanatey, Jose Ramon (author)
CIBERCV, IDIS, Univ Hosp, Cardiol Dept, Santiago De Compostela, Spain
James, Stefan, 1964- (author)
Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
Lopes, Renato D. (author)
Duke Univ, Duke Clin Res Inst, Div Cardiol, Durham, NC USA
Mehran, Roxana (author)
Icahn Sch Med Mt Sinai, Cardiovasc Inst, New York, NY 10029 USA
Montalescot, Gilles (author)
Sorbonne Univ, Pitie Salpetriere Hop, AP HP, ACTION Study Grp, Inst Cardiol, Paris, France
Patel, Manesh (author)
Duke Univ, Duke Clin Res Inst, Div Cardiol, Durham, NC USA
Steg, P. Gabriel (author)
Paris Univ, Hop Bichat, AP HP, FACT, INSERM, U1148, Paris, France
Storey, Robert F. (author)
Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England
Vranckx, Pascal (author)
Univ Hasselt, Hartctr Hasselt, Dept Cardiol & Crit Care Med, Hasselt, Belgium; Univ Hasselt, Fac Med & Life Sci, Hasselt, Belgium
Weitz, Jeffrey I. (author)
McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Biomed Sci, Hamilton, ON, Canada; Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada
Welsh, Robert (author)
Mazankowski Alberta Heart Inst, Cardiac Sci Dept, Edmonton, AB, Canada; Univ Alberta, Edmonton, AB, Canada
Zeymer, Uwe (author)
Klinikum Ludwigshafen, Ludwigshafen, Germany; Inst Herzinfarktforsch, Ludwigshafen, Germany
Angiolillo, Dominick J. (author)
Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA
show less...
 (creator_code:org_t)
2020-01-17
2020
English.
In: Nature Reviews Cardiology. - : Springer Science and Business Media LLC. - 1759-5002 .- 1759-5010. ; 17:4, s. 242-257
Related links:
https://urn.kb.se/re...
show more...
https://doi.org/10.1...
show less...
  • Research review (peer-reviewed)
Abstract Subject headings
Close  
  • Advances in antiplatelet therapies for patients with cardiovascular disease have improved patient outcomes over time, but the challenge of balancing the risks of ischaemia and bleeding remains substantial. Moreover, many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. Therefore, novel strategies are needed to prevent clinical events through mechanisms beyond platelet inhibition and with an acceptable associated risk of bleeding. The advent of non-vitamin K antagonist oral anticoagulants, which attenuate fibrin formation by selective inhibition of factor Xa or thrombin, has renewed the interest in dual-pathway inhibition strategies that combine an antiplatelet agent with an anticoagulant drug. In this Review, we highlight the emerging pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with different manifestations of cardiovascular disease, such as coronary artery disease, cerebrovascular disease and peripheral artery disease. Many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. In this Review, Angiolillo and colleagues discuss the pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with cardiovascular disease.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Publication and Content Type

ref (subject category)
for (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view